<DOC>
	<DOCNO>NCT00426920</DOCNO>
	<brief_summary>Evaluation pharmacokinetics pharmacodynamics different dos spray-dried recombinant human insulin powder inhalation administer via dry powder uinhalation device compare subcutaneously administer regular human insulin healthy male volunteer condition eugycemic clamp .</brief_summary>
	<brief_title>Investigating Pharmacokinetics Pharmacodynamics Recombinant Human Insulin Administered Dry Powder Inhaler</brief_title>
	<detailed_description>Explorative , single-center , randomize , open label , 4-way crossover study evaluate pharmacokinetics pharmacodynamics different dos spray-dried recombinant human insulin powder inhalation administer via dry powder uinhalation device compare subcutaneously administer regular human insulin healthy male volunteer condition eugycemic clamp .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>male non smoke least 12 month BMI equal less 28 clinically significant abnormality FVC FEV1 equal 80 % willing participate sign inform consent form positive result insulin antibody screen history substance abuse dependency within last 5 year positive screen test substance abuse positive blood test HIV , hepatitis B hepatitis C antibody fast blood glucose 126mg/dl exist medical condition might interfere absoprtion , distribution , metabolism excretion study medication history bronchospastic disease ( asthma ) , tachycardia , migraine headache , hypoglycemic episode , jaundice , liver disease , arterial hemorrhaging , severe hypertension hypotension , cardiac abnormality , renal disease , allergy , unresolved psychiatric illness , druginduced myopathy clinically significant abnormality receive investigational medication within 21 day prior receive first dose study medication take used prescription medication within 21 day prior receive first dose study medication take used OTC medication , vitamin herbal and/or nutritional supplement within 10 day day prior receive first dose study medication health may adversely affected procedure medication use study unwillingness inability understand follow require study restriction procedure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>inhale</keyword>
	<keyword>recombinant human insulin</keyword>
</DOC>